Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel

被引：0
|
作者：
Angelergues, A. [1 ]
Bellmunt, J. [2 ]
Efstathiou, E. [3 ]
Gonzalez, I. [4 ]
Gyftaki, R. [3 ]
Delanoy, N. [1 ]
Ozguroglu, M. [5 ]
Flechon, A. [6 ]
Guillot, A. [7 ]
Le Moulec, S. [8 ]
Castellano, D. [9 ]
Esteban, E. [10 ]
Munarriz, J. [11 ]
Campos Balea, B. [12 ]
Ardavanis, A. [13 ]
Stefanou, D. [13 ]
Oudard, S. [1 ]
机构：
[1] Georges Pompidou European Hosp, Clin Oncol, Paris, France
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Clin Oncol, Boston, MA 02115 USA
[3] Alexandra Gen Hosp Athens, Dept Oncol, Athens, Greece
[4] Univ Hosp Mar IMIM, Clin Oncol, Barcelona, Spain
[5] Istanbul Univ Cerrahpasa, Clin Oncol, Istanbul, Turkey
[6] Ctr Leon Berard, Cliin Oncol, F-69373 Lyon, France
[7] Inst Cancerol Loire, Clin Oncol, St Etienne, France
[8] Val de Grace Hosp, Clin Oncol, Paris, France
[9] Hosp Univ 12 Octubre, Clin Oncol, Madrid, Spain
[10] Hosp Univ Cent Asturias, Clin Oncol, Oviedo, Spain
[11] Hosp Prov Castellon, Clin Oncol, Castellon de La Plana, Spain
[12] Hosp Univ Lucus Augusti, Clin Oncol, Lugo, Spain
[13] St Savvas Anticancer Hosp, Clin Oncol, Athens, Greece
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31357-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2538
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [1] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
  • [4] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [6] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [7] Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer
    Lheureux, Stephanie
    Joly, Florence
    BULLETIN DU CANCER, 2012, 99 (09) : 875 - 880
  • [8] TOLERABILITY OF CABAZITAXEL IN SENIOR ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN EUROPE
    Heidenreich, A.
    Bracarda, S.
    Mason, M.
    Ozen, H.
    Sengelov, L.
    Gerritsen, W.
    Papandreou, C.
    Fossa, S.
    Hitier, S.
    Climent, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 307 - 307
  • [9] Exosome profiling reveals prognostic markers of response to cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Vardaki, I.
    Ozcan, S. Sabah
    Fonseca, P.
    Ullen, A.
    Yachnin, J.
    Panaretakis, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1368 - S1368
  • [10] Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) real data in real life
    Manneh Kopp, R.
    Alonso Gordoa, T.
    Celiz, P.
    Sepulveda, J. M.
    Grande, E.
    CastellanoGauna, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S499 - S500
12345